Riskpilot← Back to searchSign inGet full accessBioTech Development in Sweden AB
ABActiveOrg 5566619077Skaldevägen 17Computer programming activities · NACE 6210Est. 20040 employees
Revenue 2025
SEK 0
EBITDA margin
—
-117% vs 2024
Equity ratio
90.6%
Financial strength
Net profit 2025
SEK -12K
-111% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -23K | -117% |
| Net profit | SEK -12K | -111% |
| Total assets | SEK 1,6M | -14% |
| Equity | SEK 1,5M | -13% |
| Employees | 0 | — |
Legal name
BioTech Development in Sweden AB
Org number
5566619077
Legal form
Aktiebolag
NACE code
6210 · Computer programming activities
Founded
4 maj 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanterna
Company purpose
Bolagets verksamhet består av att bedriva konsultationer inom läkemedelsbranschen såsom analys, processutveckling och produktion av läkemedel, köp och förvaltning av lös och fast egendom samt därmed förenlig verksamhet.
Address
Skaldevägen 17
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 470 | 600 | 170 | 0 |
| Staff expenses | — | — | — | −19 | −0 |
| EBITDA | −11 | 460 | 572 | 134 | −23 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −11 | 460 | 572 | 134 | −23 |
| Net financials | — | 223 | −0 | 6 | 11 |
| Profit before tax | 59 | 568 | 572 | 140 | −12 |
| Tax | −13 | −71 | −118 | −31 | — |
| Net profit | 46 | 497 | 453 | 109 | −12 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 317 | 1 894 | 2 126 | 1 907 | 1 645 |
| Equity | 1 214 | 1 527 | 1 793 | 1 707 | 1 490 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 80 | 228 | 194 | 62 | 16 |
| Total debt | 80 | 228 | 194 | 62 | 16 |
EBITDA margin
-2327500.0%
This company
15.8%
Market median
-14731113% vs market
20212025
Equity ratio
90.6%
This company
38.2%
Market median
+137% vs market
20212025
Return on equity
-0.8%
This company
18.4%
Market median
-104% vs market
20212025
Net profit margin
-1217400.0%
This company
8.1%
Market median
-15029730% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BioTech Development in Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mimmi Ulrika Sewerin Ballard | Deputy Board Member | 0 companies |
| Karl Mikael Sewerin | Deputy Board Member | 0 companies |
| Karin Margareta Sewerin | Board of Directors | 0 companies |